Novel FLT3 inhibitor, displaying potent inhibitory activity against the FLT3-ITD mutant (IC 50 = 0.8 nM) and good selectivity over c-KIT kinase (over 500-fold), selectively inhibiting the proliferation of FLT3-ITD-positive AML cell lines MV4-11 (IC 50 = 2

Tumour hypoxia probe

Inhibitor of STAT3 phosphorylation and apoptotic promoter of human renal cell carcinoma and melanoma cell lines

Curcumin analogue, exhibiting enhanced growth-suppressive activity and inhibiting AKT and signal transducer and activator of transcription 3 phosphorylation in breast and prostate cancer cells

Curcumin analogue, exhibiting enhanced growth-suppressive activity and inhibiting AKT and signal transducer and activator of transcription 3 phosphorylation in breast and prostate cancer cells

Novel inhibitor of general secretion in early stage; FLI-06 analogue twice as active as FLI-06

Novel, potent, orally active, and nonsteroidal farnesoid X receptor (FXR) antagonist with propensity for accumulation and responsiveness in ileum

Natural anticancer and antioxidant

Specific inhibitor of several viruses belonging to the family of flaviviridae

Novel Inhibitor of FKBP12

Novel non-peptide bradykinin (BK)-B2 receptor antagonist

Highly potent membrane-permeable ligand of the immunophilin FKBP12, creating a new composite FKBP12-FK506 surface and inactivating calcineurin, a Ca calmodulin-dependent protein phosphatase

Fluorescent protein-protein interaction (PPI) inhibitor

Natural potent cytotoxic agent

Antibacterial agent, expressing enhanced activity at acidic pH

Cell-adhesive octapeptide as the authentic sequence within intact fibronectin, mediating OSCC cell spreading, migration, and invasion, regulating IL-17A levels and mechanical allodynia after peripheral nerve injury

Potent macrophage activator, enhancing interleukin 12-dependent interferon gamma production by lipopolysaccharide-stimulated mouse splenocytes, exerting an antiviral action against HSV-1 with the independent pathways of IFN-alpha

Fibroblast growth factor fragment

Novel light-regulated diltiazem derivative, photoswitching LTCC in pancreatic β cells, cardiomyocytes and mouse hearts

Novel inhibitor of the Wnt/β-catenin transcriptional activity, demonstrating significant increased rate of apoptosis in Huh7 and PLC/PRF

Novel regulator of transcription factor PU.1-DNA binding interactions, acting as a weak agonist that recruits PU.1 to DNA

Novel potentl and selective covalent FGFR inhibitor, inhibiting proliferation of FGFR-amplified cancer cell lines with low nM IC50 values

Novel potent and selective FGFR4 inhibitor, covalently binding to FGFR4 protein

Novel highly selective covalent inhibitor of wild-type and gatekeeper mutant FGFR4, exhibiting excellent potency against FGFR4, FGFR4V550L, and FGFR4V550M with nanomolar activity in both the biochemical and cellular assays while sparing FGFR1/2/3

Novel potent and selective covalent inhibitor of FGFR4 kinase

Novel, covalent, highly potent, and exquisitely specific FGFR4 inhibitor

Potent, reversible, ATP-competitive inhibitor against PDGFRβ, FGFR-1, and VEGFR-2 (IC50 = 20, 90, and 240 nM, respectively) and effectively suppresses VEGF-stimulated proliferation of HMVECs (EC50 = 420 nM).

Novel fluorescent probe as an excellent VMAT2 substrate capable of detecting VMAT2 activity in intact cells using fluorescence microscopy

Novel PAM-antagonist of the function of C3 at FFA3

Selective and moderately potent positive allosteric modular (PAM)-agonist of the FFA3 receptor